Your browser doesn't support javascript.
Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
Khawaja, Fareed; Papanicolaou, Genovefa; Dadwal, Sanjeet; Pergam, Steven A; Wingard, John R; Boghdadly, Zeinab El; Abidi, Maheen Z; Waghmare, Alpana; Shahid, Zainab; Michaels, Laura; Hill, Joshua A; Kamboj, Mini; Boeckh, Michael; Auletta, Jeffery J; Chemaly, Roy F.
  • Khawaja F; Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: fkhawaja@mdanderson.org.
  • Papanicolaou G; Division of Infectious Diseases, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Dadwal S; Division of Infectious Diseases, City of Hope, Duarte, California.
  • Pergam SA; Vaccine and Infectious Diseases, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Wingard JR; Division of Hematology/Oncology, University of Florida, Gainesville, Florida.
  • Boghdadly ZE; Division of Infectious Diseases, The Ohio State University College of Medicine, Columbus, Ohio.
  • Abidi MZ; Division of Infectious Diseases, University of Colorado, Boulder, Colorado.
  • Waghmare A; Division of Infectious Diseases, Seattle Children's Hospital, Seattle, Washington.
  • Shahid Z; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Michaels L; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Hill JA; Vaccine and Infectious Diseases, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Kamboj M; Division of Infectious Diseases, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Boeckh M; Vaccine and Infectious Diseases, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Auletta JJ; National Marrow Donor Program/Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota; Divisions of Hematology/Oncology/BMT and Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio.
  • Chemaly RF; Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Transplant Cell Ther ; 2022 Oct 21.
Article in English | MEDLINE | ID: covidwho-2231854
ABSTRACT
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disproportionately affects immunocompromised and elderly patients. Not only are hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell recipients at greater risk for severe COVID-19 and COVID-19-related complications, but they also may experience suboptimal immune responses to currently available COVID-19 vaccines. Optimizing the use, timing, and number of doses of the COVID-19 vaccines in these patients may provide better protection against SARS-CoV-2 infection and better outcomes after infection. To this end, current guidelines for COVID-19 vaccination in HCT and CAR T-cell recipients from the American Society of Transplantation and Cellular Therapy Transplant Infectious Disease Special Interest Group and the American Society of Hematology are provided in a frequently asked questions format.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article